G

Grand Pharmaceutical Group Ltd
HKEX:512

Watchlist Manager
Grand Pharmaceutical Group Ltd
HKEX:512
Watchlist
Price: 4.75 HKD 0.21% Market Closed
Market Cap: 16.9B HKD
Have any thoughts about
Grand Pharmaceutical Group Ltd?
Write Note

Grand Pharmaceutical Group Ltd
Intangible Assets

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Grand Pharmaceutical Group Ltd
Intangible Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Intangible Assets CAGR 3Y CAGR 5Y CAGR 10Y
G
Grand Pharmaceutical Group Ltd
HKEX:512
Intangible Assets
HK$2.2B
CAGR 3-Years
35%
CAGR 5-Years
22%
CAGR 10-Years
40%
U
United Laboratories International Holdings Ltd
HKEX:3933
Intangible Assets
ÂĄ157.7m
CAGR 3-Years
7%
CAGR 5-Years
3%
CAGR 10-Years
13%
Sino Biopharmaceutical Ltd
HKEX:1177
Intangible Assets
ÂĄ2.4B
CAGR 3-Years
38%
CAGR 5-Years
-21%
CAGR 10-Years
42%
C
China Traditional Chinese Medicine Holdings Co Ltd
HKEX:570
Intangible Assets
ÂĄ5.3B
CAGR 3-Years
-5%
CAGR 5-Years
-4%
CAGR 10-Years
18%
C
China Resources Pharmaceutical Group Ltd
HKEX:3320
Intangible Assets
HK$7.9B
CAGR 3-Years
4%
CAGR 5-Years
5%
CAGR 10-Years
N/A
H
HUTCHMED (China) Ltd
HKEX:13
Intangible Assets
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Grand Pharmaceutical Group Ltd
Glance View

Market Cap
16.9B HKD
Industry
Pharmaceuticals

Grand Pharmaceutical Group Ltd. stands as a significant player in the pharmaceutical industry, strategically positioned in the bustling hub of the Asia-Pacific region. Founded with a vision to harness scientific innovation for healing, the company has diligently expanded its reach and capabilities over the years. Grand Pharma is meticulously structured around three core segments: Medicine and Healthcare, Biopharmaceutical Manufacturing, and Medical Devices. In the Medicine and Healthcare segment, it advances an extensive portfolio of both proprietary and generic drugs. This segment alone accounts for a substantial portion of its revenue, capitalizing on its adeptness in research and development to maintain a robust pipeline of products. By continuously innovating and seeking to meet unmet medical needs, Grand Pharma sustains its competitive edge in the market. Their Biopharmaceutical Manufacturing segment shines brightly as a beacon of future growth, showcasing their commitment to biotechnology. Here, Grand Pharmaceutical leverages cutting-edge biotechnologies to develop therapies targeting a range of complex diseases. This segment is noted for its high-margin potential, driven by the increasing global demand for biologics. Furthermore, their Medical Devices segment complements the pharmaceutical operations by delivering state-of-the-art products in areas such as cardiovascular health and surgical equipment. By maintaining a balanced and diversified portfolio across these business areas, Grand Pharmaceutical effectively mitigates risks and capitalizes on emerging trends in global healthcare markets. Through astute strategic planning and an unwavering commitment to quality and innovation, the company fortifies its position as a leader in the field, continually reinvesting its profits to further enhance its offerings and broaden its impact.

Intrinsic Value
4.74 HKD
Fairly Valued
Intrinsic Value
Price
G

See Also

What is Grand Pharmaceutical Group Ltd's Intangible Assets?
Intangible Assets
2.2B HKD

Based on the financial report for Jun 30, 2024, Grand Pharmaceutical Group Ltd's Intangible Assets amounts to 2.2B HKD.

What is Grand Pharmaceutical Group Ltd's Intangible Assets growth rate?
Intangible Assets CAGR 10Y
40%

Over the last year, the Intangible Assets growth was 44%. The average annual Intangible Assets growth rates for Grand Pharmaceutical Group Ltd have been 35% over the past three years , 22% over the past five years , and 40% over the past ten years .

Back to Top